Adicet Bio (ACET) Financials: Revenue & Earnings
ACET$3.77-0.04 -1.05%
$35.29M
Market Cap
—
P/E
—
Forward P/E
—
Score
Adicet Bio (ACET) Financials: Revenue & Earnings
ACET price $3.77 -0.04 -1.05%
- Ticker
- ACET
- Price
- $3.77
- Change
- -0.04 -1.05%
- Market cap ?
- $35.29M
- Sector
- Healthcare
- Industry
- Biotechnology
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and…
Fair value
ACET fair value $33.48. Price $3.77. Price is 89% below fair value.
Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.
Calculated with a 10-year free-cash-flow discount. Starting free cash flow 3.28M. Growth 2.68%. When analyst earnings forecasts are available, free cash flow in those years is forecast earnings times the company's usual conversion of earnings into free cash flow, kept between 60% and 130%. Years with fewer than 3 analyst estimates are left out. Growth then fades in a straight line to terminal growth by year 10, starting from the last well-covered year's growth, or from the pace across those years when the final year slows sharply, kept between 0% and 20%. Without those forecasts, year-1 growth is analyst revenue growth for the next full fiscal year, or 5-year historical revenue growth when that forecast is missing, held for five years, then fading in a straight line to terminal growth by year 10. Terminal growth 3.00%. Discount rate 12.00% (beta 1.6). Beta is kept between 0.8 and 2.0, which on its own would make the discount rate 8.7% to 15.3%. The rate is then capped at 12%. A cap is used because a discount above 12% pushes higher-beta stocks further from the price. The discount rate stays at least 5 percentage points above terminal growth. Shares 9.36M. Net debt -24.18M. The earnings value is next-12-months earnings per share, or trailing earnings when that forecast is missing, times the median P/E of the company's industry. That median uses listed stocks worth at least $10 billion with a positive P/E of 100 or below, and the industry needs at least eight of them. Otherwise the sector median is used when that group also has at least eight, then the market median of those large companies. The multiple used is the lower of that median and 1.25 times the stock's own 10-year median P/E, then kept between 8 and 30. If the stock has no 10-year median, the peer median is kept between 8 and 30. Fair value is the average of the cash-flow value and the earnings value when both exist. Card and credit companies use the earnings value only, because changes in customer receivables distort free cash flow. Model uncertainty is high when fair value is more than 60% from the price, or when most of the cash-flow value sits after year 10.
Model uncertainty high for this stock
Earnings
| Date | EPS actual | EPS estimate | Revenue | Revenue estimate |
|---|---|---|---|---|
| 2026-11-04 | — | -1.56 | — | — |
| 2026-08-05 | -1.99 | -1.69 | — | — |
| 2026-05-13 | -1.88 | -2.93 | — | — |
| 2026-03-12 | -2.94 | -2.99 | — | 2.86M |
| 2025-11-05 | -4.64 | -4.16 | — | — |
| 2025-08-07 | -5.44 | -4.86 | — | — |
| 2025-05-06 | -4.96 | -5.31 | — | — |
| 2025-03-06 | -5.12 | -0.36 | — | 625.00K |
| 2024-11-06 | -5.44 | -5.45 | — | 625.00K |
| 2024-08-13 | -5.28 | -5.60 | — | 625.00K |
| 2024-05-14 | -5.60 | -0.39 | — | — |
| 2024-03-19 | -11.04 | -11.15 | — | 625.00K |
| 2023-11-08 | -11.36 | -0.74 | — | 1.11M |
| 2023-08-09 | -12.00 | -0.68 | — | 12.67M |
| 2023-05-10 | -11.52 | -0.69 | — | 4.42M |
| 2023-03-15 | -11.52 | -0.56 | — | 13.00M |
| 2022-11-08 | -0.53 | -0.53 | — | 333.33K |
| 2022-08-10 | -8.96 | -7.20 | — | 1.11M |
| 2022-05-12 | 1.60 | -0.18 | 24.99M | 14.39M |
| 2022-03-15 | -7.52 | -0.42 | 5.47M | 4.16M |
| 2021-11-10 | -7.04 | -6.08 | 3.43M | 2.89M |
| 2021-08-12 | -5.44 | -8.16 | 4.81M | 4.81M |
| 2021-05-17 | -13.12 | -8.00 | -3.98M | -3.22M |
| 2021-03-11 | -7.36 | -0.88 | 5.41M | 1.17M |
| 2020-11-05 | -45.44 | -11.84 | 3.03M | 4.10M |
| 2020-07-30 | -1.05 | -1.74 | 7.46M | 10.43M |
| 2020-05-07 | -1.33 | -2.36 | 2.00M | 2.59M |
| 2020-03-12 | -5.53 | -4.39 | 1.97M | — |
| 2019-11-05 | -4.76 | -3.76 | -7.05M | -5.17M |
| 2019-08-14 | -3.57 | -2.74 | 3.30M | — |
| 2019-05-15 | -42.55 | -40.31 | 2.77M | — |
| 2019-03-18 | -23.51 | -38.07 | -430.51M | 264.96M |
| 2018-11-13 | -33.59 | -57.10 | — | 276.36M |
| 2018-08-09 | -53.74 | -47.03 | — | 83.86M |
| 2018-05-10 | -51.50 | -32.47 | — | 129.47M |
| 2018-03-29 | -5.72 | -1.15 | -430.51M | 34.51M |
| 2017-09-30 | -1.92 | — | — | — |
| 2017-08-25 | 16.00 | — | 114.83M | — |
| 2017-05-05 | 3.20 | — | 190.13M | — |
| 2017-02-03 | -0.35 | — | 125.55M | — |
Dividends
Yield 0.00%. Payout ratio 0.00%. Frequency Quarterly.
Safety score 62/100 · Moderate. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. Dividends were paid in 10 separate years. There is no dividend yield.
| Ex-date | Dividend | Record | Payment | Frequency |
|---|---|---|---|---|
| 2018-09-21 | $0.01 | 2018-09-24 | 2018-10-09 | Quarterly |
| 2018-06-07 | $0.01 | 2018-06-08 | 2018-06-22 | Quarterly |
| 2018-03-08 | $0.07 | 2018-03-09 | 2018-03-23 | Quarterly |
| 2017-12-15 | $0.07 | 2017-12-18 | 2017-12-28 | Quarterly |
| 2017-09-07 | $0.07 | 2017-09-08 | 2017-09-21 | Quarterly |
| 2017-06-07 | $0.07 | 2017-06-09 | 2017-06-23 | Quarterly |
| 2017-03-08 | $0.07 | 2017-03-10 | 2017-03-24 | Quarterly |
| 2016-12-08 | $0.07 | 2016-12-12 | 2016-12-22 | Quarterly |
| 2016-09-07 | $0.07 | 2016-09-09 | 2016-09-20 | Quarterly |
| 2016-06-07 | $0.06 | 2016-06-09 | 2016-06-24 | Quarterly |
| 2016-03-09 | $0.06 | 2016-03-11 | 2016-03-25 | Quarterly |
| 2015-12-15 | $0.06 | 2015-12-17 | 2015-12-28 | Quarterly |
| 2015-09-17 | $0.06 | 2015-09-21 | 2015-10-02 | Quarterly |
| 2015-06-09 | $0.06 | 2015-06-11 | 2015-06-25 | Quarterly |
| 2015-03-10 | $0.06 | 2015-03-12 | 2015-03-26 | Quarterly |
| 2014-12-11 | $0.06 | 2014-12-15 | 2014-12-29 | Quarterly |
| 2014-09-11 | $0.06 | 2014-09-15 | 2014-09-29 | Quarterly |
| 2014-06-10 | $0.06 | 2014-06-12 | 2014-06-27 | Quarterly |
| 2014-03-11 | $0.06 | 2014-03-13 | 2014-03-28 | Quarterly |
| 2013-12-12 | $0.06 | 2013-12-16 | 2013-12-27 | Quarterly |
| 2013-09-12 | $0.06 | 2013-09-16 | 2013-09-27 | Quarterly |
| 2013-06-12 | $0.06 | 2013-06-14 | 2013-06-25 | Quarterly |
| 2013-03-13 | $0.06 | 2013-03-15 | 2013-03-26 | Quarterly |
| 2012-12-13 | $0.06 | 2012-12-17 | 2012-12-28 | Quarterly |
| 2012-09-13 | $0.06 | — | 2012-09-28 | Quarterly |
| 2012-06-07 | $0.10 | — | 2012-06-22 | Semi-Annual |
| 2011-12-23 | $0.10 | — | 2012-01-18 | Semi-Annual |
| 2011-06-09 | $0.10 | — | 2011-06-24 | Semi-Annual |
| 2010-12-22 | $0.10 | — | 2011-01-21 | Semi-Annual |
| 2010-06-10 | $0.10 | — | 2010-06-25 | Semi-Annual |
| 2009-12-22 | $0.10 | — | 2010-01-15 | Semi-Annual |
| 2009-06-11 | $0.10 | — | 2009-06-26 | Semi-Annual |
Insider trades
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-08-05 | Klickstein Lloyd | Buy | 18.30K | $9.16 | 167.63K |
| 2026-06-21 | DUBIN STEVE | Buy | 4.20K | $8.10 | 34.02K |
| 2026-06-21 | Chodakewitz Jeffrey | Buy | 4.20K | $8.10 | 34.02K |
| 2026-06-21 | Grissinger Michael | Buy | 4.20K | $8.10 | 34.02K |
| 2026-06-21 | Sinclair Andrew | Buy | 4.20K | $8.10 | 34.02K |
| 2026-06-21 | Peng Katie | Buy | 4.20K | $8.10 | 34.02K |
| 2026-06-21 | Klickstein Lloyd | Buy | 4.20K | $8.10 | 34.02K |
| 2026-06-19 | Schor Chen | Buy | 55.00K | $8.10 | 445.50K |
| 2026-06-19 | Aftab Blake | Buy | 55.00K | $8.10 | 445.50K |
| 2026-04-27 | RA CAPITAL MANAGEMENT, L.P. | Buy | 250.00K | $0.00 | 25 |
| 2026-04-27 | RA CAPITAL MANAGEMENT, L.P. | Sell | 250.00K | $0.00 | 25 |
| 2026-04-08 | ORBIMED ADVISORS LLC | Sell | 32.52K | $6.29 | 204.57K |
| 2026-04-08 | ORBIMED ADVISORS LLC | Sell | 40.42K | $6.52 | 263.51K |
| 2026-04-07 | ORBIMED ADVISORS LLC | Sell | 29.32K | $6.53 | 191.45K |
| 2026-04-07 | ORBIMED ADVISORS LLC | Sell | 2.40K | $6.38 | 15.31K |
| 2026-03-25 | Harvey Brian Nicholas | Buy | 43.36K | $6.81 | 295.29K |
| 2026-03-25 | Schor Chen | Buy | 468.56K | $6.81 | 3.19M |
| 2026-03-25 | Maltzman Julia D. | Buy | 72.56K | $6.81 | 494.10K |
| 2026-03-25 | Healey Don | Buy | 43.36K | $6.81 | 295.29K |
| 2026-03-25 | Aftab Blake | Buy | 72.56K | $6.81 | 494.10K |
| 2026-02-20 | RA CAPITAL MANAGEMENT, L.P. | Buy | 74.75K | $7.27 | 543.44K |
| 2026-02-19 | RA CAPITAL MANAGEMENT, L.P. | Buy | 74.27K | $7.21 | 535.47K |
| 2026-02-18 | RA CAPITAL MANAGEMENT, L.P. | Buy | 74.58K | $7.04 | 525.02K |
| 2026-02-17 | RA CAPITAL MANAGEMENT, L.P. | Other | 0 | — | — |
| 2026-02-17 | RA CAPITAL MANAGEMENT, L.P. | Other | 1.15M | $0.00 | 115 |
| 2026-01-24 | Aftab Blake | Sell | 535 | $8.44 | 4.52K |
| 2026-01-24 | Healey Don | Sell | 535 | $8.44 | 4.52K |
| 2026-01-24 | Schor Chen | Sell | 1.75K | $8.44 | 14.81K |
| 2026-01-24 | Harvey Brian Nicholas | Sell | 546 | $8.44 | 4.61K |
| 2025-10-08 | ORBIMED ADVISORS LLC | Buy | 1.50M | $1.00 | 1.50M |
| 2025-10-08 | ORBIMED ADVISORS LLC | Buy | 3.50M | $1.00 | 3.50M |
| 2025-06-11 | Klickstein Lloyd | Buy | 5.90K | — | — |
| 2025-06-11 | Klickstein Lloyd | Buy | 26.40K | $0.78 | 20.59K |
| 2025-06-11 | Chodakewitz Jeffrey | Buy | 26.40K | $0.78 | 20.59K |
| 2025-06-11 | Chodakewitz Jeffrey | Buy | 5.90K | — | — |
| 2025-06-11 | DUBIN STEVE | Buy | 26.40K | $0.78 | 20.59K |
| 2025-06-11 | DUBIN STEVE | Buy | 5.90K | — | — |
| 2025-06-11 | Peng Katie | Buy | 26.40K | $0.78 | 20.59K |
| 2025-06-11 | Peng Katie | Buy | 5.90K | — | — |
| 2025-06-11 | Sinclair Andrew | Buy | 26.40K | $0.78 | 20.59K |
| 2025-06-11 | Sinclair Andrew | Buy | 5.90K | — | — |
| 2025-04-17 | Grissinger Michael | Buy | 70.20K | $0.53 | 36.91K |
| 2025-04-17 | Grissinger Michael | Other | 0 | — | — |
| 2025-01-31 | Aftab Blake | Buy | 275.00K | $0.89 | 243.38K |
| 2025-01-31 | Schor Chen | Buy | 763.83K | $0.89 | 675.99K |
| 2025-01-31 | Healey Don | Buy | 275.00K | $0.89 | 243.38K |
| 2025-01-31 | Maltzman Julia D. | Buy | 750.00K | $0.89 | 663.75K |
| 2025-01-31 | Harvey Brian Nicholas | Buy | 324.04K | $0.89 | 286.78K |
| 2025-01-24 | Schor Chen | Sell | 28.10K | $0.92 | 25.90K |
| 2025-01-24 | Healey Don | Sell | 8.56K | $0.92 | 7.89K |
| 2025-01-24 | Aftab Blake | Sell | 6.27K | $0.92 | 5.78K |
| 2025-01-24 | Harvey Brian Nicholas | Sell | 8.75K | $0.92 | 8.07K |
| 2025-01-13 | Maltzman Julia D. | Other | 0 | — | — |
| 2024-08-21 | Sinclair Andrew | Buy | 28.83K | $15.75 | 454.04K |
| 2024-08-21 | Sinclair Andrew | Buy | 26.40K | $5.20 | 137.15K |
| 2024-08-21 | Sinclair Andrew | Buy | 18.50K | $15.93 | 294.70K |
| 2024-08-21 | Sinclair Andrew | Buy | 18.50K | $11.49 | 212.56K |
| 2024-08-21 | Sinclair Andrew | Buy | 8.17K | $15.93 | 130.18K |
| 2024-08-21 | Sinclair Andrew | Sell | 26.40K | $2.14 | 56.50K |
| 2024-08-21 | GORDON CARL L | Buy | 30.00K | $16.11 | 483.30K |
| 2024-08-21 | GORDON CARL L | Buy | 26.40K | $5.20 | 137.15K |
| 2024-08-21 | GORDON CARL L | Buy | 18.50K | $15.93 | 294.70K |
| 2024-08-21 | GORDON CARL L | Buy | 18.50K | $11.49 | 212.56K |
| 2024-08-21 | GORDON CARL L | Sell | 26.40K | $2.14 | 56.50K |
| 2024-08-21 | Peng Katie | Buy | 70.20K | $3.38 | 237.28K |
| 2024-08-21 | Peng Katie | Sell | 70.20K | $2.14 | 150.23K |
| 2024-08-21 | Chodakewitz Jeffrey | Buy | 30.00K | $16.11 | 483.30K |
| 2024-08-21 | Chodakewitz Jeffrey | Buy | 26.40K | $5.20 | 137.15K |
| 2024-08-21 | Chodakewitz Jeffrey | Buy | 18.50K | $15.93 | 294.70K |
| 2024-08-21 | Chodakewitz Jeffrey | Buy | 18.50K | $11.49 | 212.56K |
| 2024-08-21 | Chodakewitz Jeffrey | Sell | 26.40K | $2.14 | 56.50K |
| 2024-08-21 | DUBIN STEVE | Buy | 30.00K | $16.11 | 483.30K |
| 2024-08-21 | DUBIN STEVE | Buy | 26.40K | $5.20 | 137.15K |
| 2024-08-21 | DUBIN STEVE | Buy | 18.50K | $11.49 | 212.56K |
| 2024-08-21 | DUBIN STEVE | Buy | 18.50K | $15.93 | 294.70K |
| 2024-08-21 | DUBIN STEVE | Sell | 26.40K | $2.14 | 56.50K |
| 2024-08-21 | Kauffman Michael | Buy | 37.00K | $9.39 | 347.43K |
| 2024-08-21 | Kauffman Michael | Buy | 26.40K | $5.20 | 137.15K |
| 2024-08-21 | Kauffman Michael | Buy | 18.50K | $11.49 | 212.56K |
| 2024-08-21 | Kauffman Michael | Sell | 26.40K | $2.14 | 56.50K |
| 2024-08-21 | Jakobovits Aya | Buy | 30.00K | $16.11 | 483.30K |
| 2024-08-21 | Jakobovits Aya | Buy | 26.40K | $5.20 | 137.15K |
| 2024-08-21 | Jakobovits Aya | Buy | 18.50K | $15.93 | 294.70K |
| 2024-08-21 | Jakobovits Aya | Buy | 18.50K | $11.49 | 212.56K |
| 2024-08-21 | Jakobovits Aya | Sell | 26.40K | $2.14 | 56.50K |
| 2024-08-19 | Klickstein Lloyd | Buy | 70.20K | $1.55 | 108.81K |
| 2024-08-19 | Klickstein Lloyd | Sell | 0 | — | — |
| 2024-08-19 | Klickstein Lloyd | Sell | 80.00K | $2.14 | 171.20K |
| 2024-06-05 | Aftab Blake | Buy | 336.91K | $2.53 | 852.38K |
| 2024-06-05 | Galimi Francesco | Buy | 375.08K | $2.53 | 948.94K |
| 2024-06-05 | Harvey Brian Nicholas | Buy | 374.83K | $2.53 | 948.32K |
| 2024-06-05 | Healey Don | Buy | 271.60K | $2.53 | 687.14K |
| 2024-06-05 | Schor Chen | Buy | 1.77M | $2.53 | 4.48M |
| 2024-06-05 | GORDON CARL L | Buy | 26.40K | $1.44 | 38.02K |
| 2024-06-05 | GORDON CARL L | Buy | 5.90K | — | — |
| 2024-06-05 | Chodakewitz Jeffrey | Buy | 26.40K | $1.44 | 38.02K |
| 2024-06-05 | Chodakewitz Jeffrey | Buy | 5.90K | — | — |
| 2024-06-05 | Jakobovits Aya | Buy | 26.40K | $1.44 | 38.02K |
| 2024-06-05 | Jakobovits Aya | Buy | 5.90K | — | — |
| 2024-06-05 | DUBIN STEVE | Buy | 26.40K | $1.44 | 38.02K |
Institutional holders
Latest filed quarter: Q2 2026.
Institutions holding: 59, holders +10 vs prior quarter. Ownership 56.86%.
| Holder | Shares | Change | Change % | Value |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 932.62K | -250.00K | -21.14% | 8.06M |
| ORBIMED ADVISORS LLC | 844.79K | -183.16K | -17.82% | 7.30M |
| FRANKLIN TEMPLETON INC | 626.57K | 0 | 0.00% | 5.41M |
| CITADEL ADVISORS LLC | 432.74K | 50.91K | +13.33% | 3.74M |
| VANGUARD CAPITAL MANAGEMENT LLC | 343.23K | 6.70K | +1.99% | 2.97M |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 274.38K | 0 | 0.00% | 2.37M |
| RENAISSANCE TECHNOLOGIES LLC | 265.94K | 33.35K | +14.34% | 2.30M |
| STONEPINE CAPITAL MANAGEMENT, LLC | 245.52K | 23.56K | +10.62% | 2.12M |
| ALYESKA INVESTMENT GROUP, L.P. | 203.80K | 0 | 0.00% | 1.76M |
| SCHONFELD STRATEGIC ADVISORS LLC | 195.51K | 195.51K | New | 1.69M |
| CARLYLE GROUP INC. | 184.29K | 0 | 0.00% | 1.59M |
| NEXTBIO CAPITAL MANAGEMENT LP | 157.83K | 0 | 0.00% | 1.36M |
| ACADIAN ASSET MANAGEMENT LLC | 124.83K | 6.69K | +5.67% | 1.08M |
| TWO SIGMA INVESTMENTS, LP | 96.84K | 53.73K | +124.65% | 836.69K |
| GEODE CAPITAL MANAGEMENT, LLC | 95.63K | -5.50K | -5.44% | 826.70K |
| DAFNA CAPITAL MANAGEMENT LLC | 93.81K | 0 | 0.00% | 810.54K |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 85.96K | 85.96K | New | 742.69K |
| MARSHALL WACE, LLP | 79.49K | 79.49K | New | 686.77K |
| TREXQUANT INVESTMENT LP | 78.00K | 34.34K | +78.63% | 673.94K |
| JANE STREET GROUP, LLC | 70.56K | 33.48K | +90.27% | 609.65K |
| BURKEHILL GLOBAL MANAGEMENT, LP | 62.50K | 0 | 0.00% | 540.00K |
| BLACKROCK, INC. | 62.13K | 25.54K | +69.81% | 536.77K |
| REGENERON PHARMACEUTICALS, INC. | 60.51K | 60.51K | New | 522.82K |
| RANGELEY CAPITAL, LLC | 50.89K | -5.11K | -9.12% | 439.71K |
| VANGUARD FIDUCIARY TRUST CO | 50.67K | 336 | +0.67% | 437.79K |
Earnings and financials
Adicet Bio, Inc. (ACET) trades at $3.77, with a market cap of $35.29M and a trailing P/E of n/a. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.
Insights · Dividends · Forecast · Financials · Learn